Mesothelioma Therapy Diagnosis and Biomarkers for Mesothelioma 3

Question 1

Which serum biomarker is most widely studied and used to monitor mesothelioma disease progression and treatment response?

Accepted Answer

Soluble mesothelin-related peptides (SMRP)

Answer

Soluble mesothelin-related peptides (SMRP), measured by the FDA-cleared Mesomark assay, are the most widely studied serum biomarker for monitoring disease activity and treatment response in mesothelioma.

Question 2

Approximately what is the sensitivity of serum soluble mesothelin-related peptides (SMRP) for diagnosing mesothelioma?

Accepted Answer

Approximately 50-70%

Answer

Serum SMRP has a sensitivity of approximately 50-70% for mesothelioma, meaning it misses a substantial proportion of cases and cannot serve as a standalone diagnostic test.

Question 3

Which biomarker has been found elevated in both plasma and pleural fluid of mesothelioma patients and proposed as an additional diagnostic marker?

Accepted Answer

Fibulin-3

Answer

Fibulin-3, an extracellular matrix glycoprotein, has been found elevated in both plasma and pleural fluid of mesothelioma patients, though it is not yet FDA-approved as a standalone diagnostic biomarker.

Question 4

Why is BAP1 (BRCA1-associated protein 1) immunohistochemical testing clinically important in mesothelioma pathology?

Accepted Answer

Loss of BAP1 nuclear expression supports malignant mesothelioma over reactive mesothelial hyperplasia

Answer

Loss of BAP1 nuclear expression detected by immunohistochemistry is a highly specific marker supporting malignant mesothelioma over benign reactive mesothelial proliferation, aiding in a diagnostically challenging distinction.

Question 5

What is the diagnostic significance of homozygous deletion of CDKN2A (p16) detected by fluorescence in situ hybridization (FISH) in pleural specimens?

Accepted Answer

It supports malignant mesothelioma over reactive mesothelial hyperplasia as a highly specific chromosomal marker

Answer

Homozygous deletion of CDKN2A (p16) detected by FISH is a highly specific finding that strongly supports malignant mesothelioma over reactive mesothelial proliferation when tissue diagnosis is equivocal.

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Diagnosis and Biomarkers for Mesothelioma 3